Bristol-Myers Squibb Analyst Ratings
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,025 to $1,113
Jefferies Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Cuts Target Price to $51
Hold Rating on Bristol-Myers Squibb Amid Patent Expirations and Speculative Prospects of Milvexian
Eli Lilly & Co: Strategic Pricing and Market Expansion Fuel Buy Rating
Eli Lilly Analyst Ratings
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Eli Lilly & Co (LLY) Receives a Buy From Barclays
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $115
Bristol-Myers Squibb Analyst Ratings
Axsome Therapeutics Analyst Ratings
Buy Rating on Axsome Therapeutics: Legal Wins and Positive Clinical Trial Outlook Secure Market Position
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $180
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Announces Target Price $42
Barclays Reaffirms Their Sell Rating on Bristol-Myers Squibb (BMY)
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,101
Intra-Cellular Therapies Analyst Ratings
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,101
Jefferies Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
J.P. Morgan Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $81